Drug intelligence / Profile preview

NTT-005

Development stage: Preclinical
Lead developer: NTT Biopharma
Modality: Nanoparticles → Drug Delivery Systems, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

NTT-005 is an experimental, preclinical-stage targeted nanoparticle therapy developed by NTT Biopharma for the treatment of solid tumors, with a primary focus on breast cancer. The platform utilizes mesoporous silica nanoparticles (MSN) that are functionalized with antibody Fab fragments (Fab-MSN) to facilitate active targeting of cancer cells. This approach aims to enhance the delivery of therapeutic agents directly to the tumor microenvironment while minimizing off-target effects and systemic toxicity. The specific molecular target of the Fab fragment and the therapeutic payload encapsulated within the MSN have not been publicly disclosed.

Other names: Fab-conjugated mesoporous silica nanoparticles

Beyond the preview

Go deeper on NTT-005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NTT-005.

Explore the full profile